By PPN news staff
The FDA approved benralizumab (Fasenra, AstraZeneca/MedImmune) for the add-on maintenance treatment of patients with severe eosinophilic phenotype asthma, aged 12 years and older.
Benralizumab is a monoclonal antibody that recruits natural killer cells to induce direct, rapid and near-complete depletion of eosinophils. Depletion of circulating eosinophils is rapid, with an onset of action within 24 hours. Benralizumab is not approved for the treatment of other eosinophilic